Company · Healthtech & Bio

Emily.AI

emilycares.ai ↗ ·Barcelona ·Seed

Emily.AI is a Barcelona-based medtech startup building an explainable AI-driven closed-loop platform that continuously monitors 40+ physiological parameters to personalize long-term oxygen therapy for chronic respiratory patients (e.g. COPD) in hospital and home settings. Founded in 2021, it is still early-stage (working prototype, small pre-seed/seed round, ~8 employees) and has won recognition from Cuatrecasas Acelera and was a finalist at the UN's AI for Good Global Summit 2026.

Founded

2021

Founders

News

Rounds

Investors

SectorsHealthtech, Digital Health, Medical Devices, AI, Remote Patient Monitoring Start-up MapHealthtech & Bio › Medical devices & surgical hardware

Profile updated 29 Jul 2026

Founders

Daniel Oliva Laucirica

Founder & CEO

Rodolfo Campos

Partner & CTO

Global models 5

Hinge Health

United States · www.hingehealth.com ↗

AI-driven digital platform that continuously monitors patient data (via sensors) to personalize and adjust a chronic-condition therapy plan in real time, same closed-loop model applied to MSK instead of respiratory care.

$1.05BComparable

Biofourmis

United States · biofourmis.com ↗

AI-powered remote patient monitoring platform that continuously analyzes physiological data to personalize chronic-disease care, directly analogous to Emily.AI's approach but across broader chronic conditions.

$445MComparable

Livongo Health

United States · www.livongo.com ↗

Connected-device platform that continuously collects patient biometrics to deliver personalized, AI-informed chronic disease management, later acquired by Teladoc for $18.5B.

$235MComparable

Current Health

United Kingdom · currenthealth.com ↗

Wearable-based remote monitoring platform tracking vitals including oxygen saturation and respiration rate to flag at-risk patients, closely matching Emily.AI's monitoring approach.

$79.1MComparable

Propeller Health

United States · www.propellerhealth.com ↗

Connected sensor platform specifically for COPD and asthma management, the closest direct sector comparable to Emily.AI, acquired by ResMed for $225M.

$64MComparable